

PUBLIC SUBMISSION

As of: 4/22/26, 2:46 PM
Received: April 05, 2026
Status: Draft
Tracking No. mnm-kj7u-odkr
Comments Due: April 21, 2026
Submission Type: API

Docket: FDA-2026-N-1305

Agency Information Collection Activities; Proposed Collection; Comment Request; New Animal Drugs for Minor Use and Minor Species

Comment On: FDA-2026-N-1305-0001

Agency Information Collection Activities; Proposed Collection; Comment Request; New Animal Drugs for Minor Use and Minor Species

Document: FDA-2026-N-1305-DRAFT-0001

Comment from Anonymous

Submitter Information

Name: Anonymous Anonymous

General Comment

I support the FDA's proposal on fixing the lack of clear information companies have about drugs that are used on rare species because it improves how the drugs are reviewed and regulated for the animals. Drugs that are used on animals that are uncommon on earth are often overlooked and they don't have a clear plan of action for them. It can be difficult to guarantee the safety of these animals if there are not enough precautions taken. By forcing the companies to follow a list of rules and submitting detailed information, it can help create a more reliable system for the animals. I believe that having this rule is positively impacting the animal and guaranteeing them a longer lifespan.

This rule is important because it guarantees that the companies provide enough data for the FDA to look over the animal drugs. In the past, there has been unclear information and reports made about drugs given to animals, and it is hard to know if these drugs are actually safe. By requiring companies to submit reports and following specific procedures, the FDA can make sure they take the right course of action when it comes to drugs for rare animals. This not only protects species, but also helps veterinarians and animal owners feel more comfortable with what they are giving their animals.

Although the rule improves safety and makes the system organized, it also brings along some challenges for smaller companies, such as more paperwork and the increase in price. I think the FDA should shorten the reporting process or help small businesses meet the requirements that are needed for the animal drugs. For example, they could provide clear templates or make guides to help companies have an easier path to reporting drugs. By adding these additions, the FDA can maintain a high level of safety while also ensuring that it is possible for small companies to go through this process. By doing all this, drugs can be given to rare animals in a safe and efficient way.